<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920656</url>
  </required_header>
  <id_info>
    <org_study_id>20 KHCC 202</org_study_id>
    <nct_id>NCT04920656</nct_id>
  </id_info>
  <brief_title>Universal Genetic Testing Versus Guidelines-Directed Testing for Germline Pathogenic Variants Among Non-Western Patients With Breast Cancer</brief_title>
  <official_title>Universal Genetic Testing Versus Guidelines-Directed Testing for Germline Pathogenic Variants Among Non-Western Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Hussein Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Hussein Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to examinethe pattern and frequency of pathogenic variants among all newly&#xD;
      diagnosed breast cancer patients in a genetically distinct population. Additionally, the&#xD;
      uptake rate of &quot;cascade family screening&quot; , frequency of pathogenic variants and barriers&#xD;
      against testing will be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of pathogenic or likely pathogenic germline variants among newly diagnosed breast cancer patients tested by universal multigene panel testing or guideline-based targeted testing</measure>
    <time_frame>2021-2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with variants of uncertain significance (VUS) as assessed by universal multigene panel testing versus guideline-based targeted testing</measure>
    <time_frame>2021-2023</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The reasons/ Barriers for refusal of genetic cascade testing among newly diagnosed cancer patients</measure>
    <time_frame>2021-2023</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of cascade testing of family members of the participants with positive pathogenic mutation</measure>
    <time_frame>2021-2023</time_frame>
    <description>The family of the positive patients will be offered the genetic testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of pathogenic or likely pathogenic mutations among family members of the patients with pathogenic mutations using the universal multigene panel</measure>
    <time_frame>2021-2023</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of variants of uncertain significance (VUS) among tested family members of participants with pathogenic mutations as assessed by universal multigene panel testing</measure>
    <time_frame>2021-2023</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reasons/ Barriers for refusal of genetic cascade testing among family members of the tested patients with pathogenic mutations</measure>
    <time_frame>2021-2023</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast cancer patients</arm_group_label>
    <description>All adult patients with a confirmed diagnosis of breast cancer, aged 18 or older at time of cancer diagnosis, will be invited to participate.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients who fulfill the inclusion/exclusion criteria, and are treated and&#xD;
        followed up at KHCC will be invited.&#xD;
&#xD;
        A total of 1000 patients are estimated to participate&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient, age â‰¥ 18 years at time of cancer diagnosis&#xD;
&#xD;
          -  Pathology proven diagnosis of breast cancer (including DCIS); any stage. (prior&#xD;
             history of cancer is allowed)&#xD;
&#xD;
          -  Willingness to participate&#xD;
&#xD;
          -  Signed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Major psychiatric disorder (defined as: patients followed by a psychiatrist and on&#xD;
        antipsychotic medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Hikmat Abdel-Razeq</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Hussein Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hikmat Abdel-Razeq</last_name>
    <phone>(06) 530 0460</phone>
    <phone_ext>1000</phone_ext>
    <email>habdelrazeq@khcc.jo</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rayan Bater</last_name>
    <phone>0790554973</phone>
    <email>rb.14307@khcc.jo</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <zip>11941</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hikmat Abdel-Razeq</last_name>
      <email>habdelrazeq@khcc.jo</email>
    </contact>
    <contact_backup>
      <phone_ext>Abdel-Razeq</phone_ext>
      <email>habdelrazeq@khcc.jo</email>
    </contact_backup>
    <investigator>
      <last_name>Hikmat Abdel-Razeq</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Hussein Cancer Center</investigator_affiliation>
    <investigator_full_name>Hikmat Abdel-Razeq</investigator_full_name>
    <investigator_title>Professor, Chairman of department of medicine, Chief Medical officer, Deputy Director General</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

